公开(公告)号：US20120130303A1

公开(公告)日：2012-05-24

申请号：US13359949

申请日：2012-01-27

申请人： Vinod Sharma ,  Daniel C. Sigg

发明人： Vinod Sharma ,  Daniel C. Sigg

IPC分类号： A61K31/7052 ,  A61P9/00 ,  A61N1/362 ,  A61K35/00

CPC分类号： A61N1/362 ,  A61K9/0019 ,  A61K31/221 ,  A61K38/177 ,  A61N1/0568

摘要： A biologic intervention method and apparatus generates a persistent modification to an AV node that is physiologically stable after the agent has matured but is alterable with subsequent application of an agent. Specifically, the generic agent is used to modulate a node in a cardiac conduction system including rate control using one and a combination of a family of K+ channel or equivalent. Specifically, the channel is implemented to slow conduction by generating an outward current during optimization of action potential and repolarization phase thus decreasing the current that is available to excite downstream cells. A Kv 1.3 channel, for example, may be used as the biologic channel. The invention enables reversal of the modulation or adjustment for various heart rates (BPM) based on medical and patient-specific needs.

摘要翻译： 生物干预方法和装置对于在该药剂已经成熟但随后随后施用药剂而可变化的生理稳定的AV节点产生持久性修饰。 具体地，通用代理用于调制心脏传导系统中的节点，包括使用一个K +通道或等效物系的组合的速率控制。 具体地，通过在动作电位和复极相优化期间产生向外的电流来实现缓慢传导，从而减少可用于激发下游单元的电流。 例如，可以使用Kv1.3通道作为生物通道。 本发明能够根据医疗和患者特定的需要逆转各种心率（BPM）的调节或调整。

公开(公告)号：US08170663B2

公开(公告)日：2012-05-01

申请号：US11687282

申请日：2007-03-16

申请人： Paul J. DeGroot ,  Kevin T. Ousdigian ,  Vasant Padmanabhan ,  Paul Krause ,  Vinod Sharma

发明人： Paul J. DeGroot ,  Kevin T. Ousdigian ,  Vasant Padmanabhan ,  Paul Krause ,  Vinod Sharma

IPC分类号： A61N1/362 ,  A61N1/39

CPC分类号： A61N1/3622 ,  A61N1/3688 ,  A61N1/3925 ,  A61N1/3956 ,  A61N1/3962 ,  A61N1/3987

摘要： A system and method for delivering both anti-tachy pacing (ATP) therapy and high-voltage shock therapy in response to detection of abnormal cardiac rhythms is disclosed. The system controls the time between delivering ATP therapy and the charging of high-voltage capacitors in preparation for shock delivery based on a predetermined set of criteria. In one embodiment, the inventive system operates in an ATP During Capacitor Charging (ATP-DCC) mode wherein all, or substantially all, of the ATP therapy is delivered during charging of the high-voltage capacitors. Based on evaluation of the predetermined set of criteria, the system may switch to an additional ATP Before Capacitor Charging (ATP-BCC) mode, wherein substantially all of the ATP therapy is delivered prior to charging of the high-voltage capacitor. According to one aspect of the invention, the predetermined set of criteria is based, at least in part, on the effectiveness of previously-delivered ATP therapy.

摘要翻译： 公开了一种用于响应于异常心律的检测而提供抗起搏起搏（ATP）治疗和高压休克疗法的系统和方法。 该系统基于预定的一组标准来控制ATP治疗与高压电容器的充电之间的时间，以准备冲击输送。 在一个实施例中，本发明的系统在ATP电容器充电（ATP-DCC）模式下工作，其中在高压电容器充电期间全部或基本上全部ATP治疗被递送。 基于对预定标准集合的评估，系统可以切换到在电容器充电（ATP-BCC）模式之外的另外的ATP，其中在高压电容器充电之前基本上全部ATP治疗被递送。 根据本发明的一个方面，预定的一组标准至少部分地基于先前传递的ATP治疗的有效性。

公开(公告)号：US08076305B2

公开(公告)日：2011-12-13

申请号：US11565433

申请日：2006-11-30

申请人： Daniel C. Sigg ,  Vinod Sharma ,  Yong-Fu Xiao

发明人： Daniel C. Sigg ,  Vinod Sharma ,  Yong-Fu Xiao

IPC分类号： A61K48/00 ,  A01N63/00 ,  C12N15/74 ,  C07H21/04

CPC分类号： A61K48/005 ,  A61K38/00 ,  C07K14/705

摘要： A composition for implantation into cardiac tissue includes a biological pacemaker that, when implanted, expresses an effective amount of a mutated hyperpolarization-activated and cyclic nucleotide-gated (HCN) isoform to modify Ih when compared with wild-type HCN. Methods for implementing each of the biologocal pacemakers include implanting each of biologocal pacemakers into cardiac tissue.

摘要翻译： 用于植入心脏组织的组合物包括生物起搏器，当植入时，与野生型HCN相比，表达有效量的突变超极化激活和环核苷酸门控（HCN）同种型以修饰Ih。 实现每个生物定位心脏起搏器的方法包括将每个生物定位心脏起搏器植入心脏组织。

公开(公告)号：US07894899B2

公开(公告)日：2011-02-22

申请号：US12393059

申请日：2009-02-26

申请人： Vinod Sharma

发明人： Vinod Sharma

IPC分类号： A61N1/362

CPC分类号： A61N1/3622 ,  A61N1/3962

摘要： An implantable device for terminating ventricular tachycardia is disclosed. The device includes a processor configured to determine a first antitachycardia pulse routine of N pulses. In the routine the first N−1 pulses are separated by a first cycle length and the Nth pulse is separated by a second cycle length that is shorter than the first cycle length. The device also comprises a lead coupled to the processor. The lead comprises an electrode configured to sense a tachycardia and further configured, under control of the processor, to administer the antitachycardia pulse routine.

摘要翻译： 公开了用于终止室性心动过速的可植入装置。 该装置包括被配置为确定N个脉冲的第一抗心动过速脉冲程序的处理器。 在该例程中，第一N-1个脉冲被第一周期长度分开，并且第N个脉冲被分开比第一周期长度短的第二周期长度。 该装置还包括耦合到处理器的引线。 引线包括被配置为感测心动过速的电极，并且在处理器的控制下进一步配置以施用抗心动过速脉冲程序。

公开(公告)号：US20100076063A1

公开(公告)日：2010-03-25

申请号：US12578198

申请日：2009-10-13

申请人： Vinod Sharma ,  Walter H. Olson

发明人： Vinod Sharma ,  Walter H. Olson

IPC分类号： A61K31/7088 ,  A61P9/10

CPC分类号： C07K14/705 ,  A61K38/00 ,  A61K38/177

摘要： Disclosed are compositions, methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of cells of targeted regions of the cardiac conduction system. In particular, a bio-pacemaker composition is delivered to cardiac cells to increase the intrinsic pacemaking rate of the cells, wherein the bio-pacemaker composition increases expression of a channel or subunit thereof that produces funny current and a T-type Ca2+ channel or subunit thereof, and expresses one or more molecules that suppresses the expression of the wild type potassium channel.

摘要翻译： 公开了用于预防或治疗心脏功能障碍的组合物，方法和系统，特别是心脏起搏功能障碍，通过心脏传导系统的靶向区域的细胞的遗传修饰。 特别地，将生物起搏器组合物递送到心脏细胞以增加细胞的固有起搏速率，其中生物起搏器组合物增加产生滑稽电流的通道或其亚基的表达，以及T型Ca 2+通道或亚基 并表达抑制野生型钾通道表达的一种或多种分子。

公开(公告)号：US20100047915A1

公开(公告)日：2010-02-25

申请号：US12606173

申请日：2009-10-26

申请人： Orhan Soykan ,  Amy C. Dearking ,  Timothy H. Robinson ,  Walter H. Olson ,  Vinod Sharma

发明人： Orhan Soykan ,  Amy C. Dearking ,  Timothy H. Robinson ,  Walter H. Olson ,  Vinod Sharma

IPC分类号： G01N33/00

CPC分类号： G01N33/6893 ,  G01N2800/326

摘要： The invention is a method for identifying proteins associated with sudden cardiac death (SCD) and for assessing a patient's risk of SCD by determining the amount of one or more SCD-associated proteins in the patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more SCD-associated proteins. Based upon the results of the tests, the patient's risk of SCD may be assessed.

摘要翻译： 本发明是鉴定与心脏猝死相关的蛋白质（SCD）的方法，并且通过确定患者中一种或多种与SCD相关的蛋白质的量来评估患者的SCD风险。 通常，患者提交样品，例如血液样品，其被测试一种或多种与SCD相关的蛋白质。 根据测试结果，可以评估患者SCD的风险。

公开(公告)号：US07608458B2

公开(公告)日：2009-10-27

申请号：US11157549

申请日：2005-06-21

申请人： Orhan Soykan ,  Amy C. Dearking ,  Timothy H. Robinson ,  Walter H. Olson ,  Vinod Sharma

发明人： Orhan Soykan ,  Amy C. Dearking ,  Timothy H. Robinson ,  Walter H. Olson ,  Vinod Sharma

IPC分类号： G01N33/00

CPC分类号： G01N33/6893 ,  G01N2800/326

摘要： The invention is a method for identifying proteins associated with sudden cardiac death (SCD) and for assessing a patient's risk of SCD by determining the amount of one or more SCD-associated proteins in the patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more SCD-associated proteins. Based upon the results of the tests, the patient's risk of SCD may be assessed.

摘要翻译： 本发明是鉴定与心脏猝死相关的蛋白质（SCD）的方法，并且通过确定患者中一种或多种与SCD相关的蛋白质的量来评估患者的SCD风险。 通常，患者提交样品，例如血液样品，其被测试一种或多种与SCD相关的蛋白质。 根据测试结果，可以评估患者SCD的风险。

公开(公告)号：US07583468B2

公开(公告)日：2009-09-01

申请号：US11270940

申请日：2005-11-10

申请人： Vinod Sharma ,  Hyung Jai Lee ,  Dong Jun Lee

发明人： Vinod Sharma ,  Hyung Jai Lee ,  Dong Jun Lee

IPC分类号： G11B5/596

CPC分类号： G11B5/5552 ,  G11B5/596

摘要： A magnetic head follows a track in a hard disk drive as positioned by micro-actuator and voice coil motor. Embodiments operate two control paths. The micro-actuator control path generates a version of micro-actuator control signal stimulating the micro-actuator. The voice coil motor control path generates a version of voice coil control signal, amplified based upon tuning gain to stimulate voice coil motor. A decoupling feedback filter decouples these control paths, using the micro-actuator control signal version. Either control path may include a notch filter. A track following command, with PES removed, directs the micro-actuator control. The servo-controller may digitally support the invention, which may include the servo-controller program system. An implementation may be optimized within a hard disk drive, possibly as part of the manufacturing process. The hard disk drive is a product of that process.

摘要翻译： 磁头跟随由微型致动器和音圈电机定位的硬盘驱动器中的轨道。 实施例操作两个控制路径。 微致动器控制路径产生刺激微致动器的微致动器控制信号的形式。 音圈电机控制路径产生一个版本的音圈控制信号，根据调谐增益放大，以刺激音圈电机。 去耦反馈滤波器使用微执行器控制信号版本解耦这些控制路径。 控制路径可以包括陷波滤波器。 一个跟踪命令，取消了PES，指示微执行器控制。 伺服控制器可以数字支持本发明，其可以包括伺服控制器程序系统。 可以在硬盘驱动器内优化实现，可能是制造过程的一部分。 硬盘驱动器是该进程的产物。

公开(公告)号：US07415307B2

公开(公告)日：2008-08-19

申请号：US10284900

申请日：2002-10-31

申请人： Vinod Sharma ,  Walter H. Olson

发明人： Vinod Sharma ,  Walter H. Olson

IPC分类号： A61N1/00

CPC分类号： A61B5/05 ,  A61B5/7203 ,  A61N1/362

摘要： Methods and process for detection of myocardial ischemia involve detection and analysis of changes in electrical conduction velocity within the heart to monitor changes in the condition of the cardiac muscle and indicate possible ischemia. Conduction velocity slows considerably when oxygen supply to the heart is reduced. Analysis of electrical conduction velocity can be used to verify the occurrence of myocardial ischemia in a more reliable manner. Changes in conduction velocity may be monitored based on conduction time between electrodes positioned in the left and right ventricles of the heart. The electrodes may be endocardial or epicardial electrodes. In general, the techniques may involve launching a stimulation waveform at one electrode and sensing a local cardiac depolarization at another electrode to assess conduction time.

摘要翻译： 用于检测心肌缺血的方法和过程涉及检测和分析心脏内电传导速度的变化，以监测心肌状况的变化并指示可能的缺血。 当心脏供氧减少时，传导速度显着减慢。 电传导速度分析可以更可靠地验证心肌缺血的发生。 可以基于位于心脏左心室和右心室的电极之间的传导时间来监测传导速度的变化。 电极可以是心内膜或心外膜电极。 通常，这些技术可以涉及在一个电极处发射刺激波形并感测另一个电极处的局部心脏去极化以评估传导时间。

公开(公告)号：US20080103537A1

公开(公告)日：2008-05-01

申请号：US11554770

申请日：2006-10-31

申请人： Daniel C. Sigg ,  Timothy G. Laske ,  Vinod Sharma ,  Orhan Soykan

发明人： Daniel C. Sigg ,  Timothy G. Laske ,  Vinod Sharma ,  Orhan Soykan

IPC分类号： A61N1/00

CPC分类号： A61N1/362 ,  A61N1/3627

摘要： Heart pacing systems include at least one electronic or biological pacemaker as a primary pacemaker, and at least one electronic or biological pacemaker as a backup pacemaker. When implanted, the primary pacemaker(s) produce primary pacing stimuli that modulate cardiac function. The backup pacemaker(s) provide backup pacing stimuli when the electronic pacemaker is unable to modulate cardiac function at the predetermined pacing rate. The heart pacing systems are implemented by implantation in regions where they can provide pacing stimuli to cardiac tissue.

摘要翻译： 心脏起搏系统包括至少一个电子或生物起搏器作为主要起搏器，以及至少一个电子或生物起搏器作为备用起搏器。 当植入时，主起搏器产生调节心脏功能的主要起搏刺激。 当电子起搏器不能以预定起搏速度调节心脏功能时，备用起搏器提供备用起搏刺激。 心脏起搏系统通过植入在可以为心脏组织提供起搏刺激的区域中实现。